Safety net hospital risk model demonstrates stronger, population-specific applicability in characterizing lung cancer risk
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new lung cancer (LC) risk model developed for safety net hospital (SNH) populations shows higher specificity than the PLCO model. This highlights the importance of representative data in developing effective LC screening tools.
Area Of Science
- Oncology
- Public Health
- Biostatistics
Background
- Personalized lung cancer (LC) risk stratification can enhance screening effectiveness.
- The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) model, derived from a Caucasian population, may not be optimal for diverse populations.
- The effectiveness of existing LC risk models in safety net hospital (SNH) settings is largely unknown.
Purpose Of The Study
- To develop and evaluate a novel LC risk stratification model tailored for an SNH population.
- To compare the performance of the SNH-specific model against the established PLCO model within an SNH setting.
Main Methods
- A retrospective dataset of 896 patients screened for LC at an SNH between 2015-2019 was analyzed.
- Key variables included age, sex, race, BMI, smoking history, cancer history, COPD, and emphysema.
- LC risk scores were calculated using both SNH and PLCO models, and performance metrics (sensitivity, specificity) were compared.
Main Results
- The SNH population comprised predominantly African Americans (53.5%), current smokers (69.9%), and individuals with emphysema (70.1%).
- The SNH model demonstrated significantly higher specificity (96.8%) compared to the PLCO model (26.1%) in characterizing LC risk.
- Emphysema was strongly associated with LC risk in the SNH model (P<0.001), whereas race showed no significant relation.
Conclusions
- The developed SNH model exhibits superior specificity for lung cancer risk assessment in SNH populations.
- This study underscores the critical need for representative sample data in developing accurate risk stratification models for diverse patient groups.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
Descriptive Statistics: These provide basic...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...